Dynavax (DVAX) was downgraded to a Hold Rating at William Blair
Dynavax received a Hold rating and price target from William Blair analyst Matt Phipps today.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Phipps covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Incyte, and Merus. According to TipRanks, Phipps has an average return of 4.8% and a 49.29% success rate on recommended stocks.
Currently, the analyst consensus on Dynavax is a Moderate Buy with an average price target of $20.50.
Based on Dynavax’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $94.88 million and a net profit of $26.93 million. In comparison, last year the company earned a revenue of $80.63 million and had a net profit of $17.59 million
Read More on DVAX:
Disclaimer & DisclosureReport an Issue
- Dynavax jumps 37% to $15.31 after buyout offer from Sanofi
- Sanofi to acquire Dynavax for $15.50 per share in cash, or $2.2B
- Sanofi (SNY) Acquires Dynavax in $2.2 Billion Deal after FDA Rebuff
- Dynavax Technologies Reports Strong Q3 Earnings and Strategic Growth
- Dynavax’s Promising Growth and Strategic Initiatives Justify Buy Rating with $25 Target
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.